A unique feature of our study is that the clinical and biological relevance of TACSTD2 as a regulator of HCV entry is corroborated by a series of in vivo observations that we made in primary tumor tissue obtained at the time of liver explant or resection from well-characterized patients with HCC. Here, TACSTD2 is linked to neoplasm.